Monument Capital Management acquired a new stake in Johnson & Johnson (NYSE:JNJ – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,332 shares of the company’s stock, valued at approximately $386,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlantic Private Wealth LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $32,000. Dark Forest Capital Management LP lifted its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson in the fourth quarter worth approximately $45,000. Finally, 25 LLC acquired a new stake in Johnson & Johnson in the first quarter worth approximately $55,000. 68.40% of the stock is owned by institutional investors.
Johnson & Johnson Stock Performance
NYSE:JNJ opened at $155.75 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $404.79 billion, a P/E ratio of 31.53, a price-to-earnings-growth ratio of 3.15 and a beta of 0.55. The firm has a 50 day moving average of $165.97 and a 200-day moving average of $162.29. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Analyst Upgrades and Downgrades
Several research firms have issued reports on JNJ. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 18th. Finally, HSBC assumed coverage on shares of Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $170.65.
Get Our Latest Stock Report on JNJ
Insiders Place Their Bets
In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Further Reading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.